Clinical Takeaway
In a small, double-blind, placebo-controlled pilot trial of 24 adults with fibromyalgia, a 1:1 THC:CBD cannabis oil was found to be feasible and generally well-tolerated over a 16-week period that included a 4-week dose titration phase. Secondary outcomes provided preliminary signals regarding symptom relief across multiple fibromyalgia domains, though the study was not powered to establish definitive efficacy. These findings support the rationale for larger, adequately powered randomized trials to evaluate cannabinoid therapy as a structured treatment option for fibromyalgia.
#11 Feasibility, Safety and Preliminary Efficacy of 1:1 THC:CBD Cannabis Oil for Fibromyalgia Symptoms: Results From a Randomised, Double-Blind, Placebo-Controlled Pilot Trial.
Citation: Kurlyandchik Inna et al.. Feasibility, Safety and Preliminary Efficacy of 1:1 THC:CBD Cannabis Oil for Fibromyalgia Symptoms: Results From a Randomised, Double-Blind, Placebo-Controlled Pilot Trial.. Pain research & management. 2026. PMID: 42142029.
Design: 5 Journal: 2 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Methodological Considerations:
- Small sample — underpowered for subgroup analysis
Abstract: Fibromyalgia is a chronic disorder characterised by widespread pain and other symptoms that substantially impact the quality of life. This double-blind, randomised, placebo-controlled trial primarily assessed feasibility (procedures and intervention adherence) and safety/tolerability of a 1:1 delta-9-tetrahydrocannabinol:cannabidiol (THC:CBD) cannabis oil (10 mg/mL each) in 24 adults with fibromyalgia, with secondary, preliminary assessment of efficacy across symptom domains. Participants completed a 4-week dose titration followed by 12 weeks of stable dosing. Of 77 prescreened individuals, 24 were randomised, yielding a screening-to-enrolment ratio of approximately 3:1 (31.2%). Recruitment reached 66.7% of the target (24/36); the shortfall was mainly due to geographic and legal barriers. Retention was 91.7% (22/24) and adherence was high, with all participants taking ≥ 90% of the prescribed doses. The study medication was well tolerated in this small sample, with adverse events mostly mild and no serious events observed. Secondary outcomes suggested medium to large between-group effects favouring cannabis for pain reduction, improved sleep quality, and reduced fibromyalgia impact (FIQR), but findings should be interpreted cautiously given the small sample. Clinically meaningful FIQR improvement (predefined MCID 45.5%) occurred in 40% of the cannabis-treated participants versus 10% with placebo. For pain, 70% of the cannabis group reported ≥ 30% reduction post-titration and at Week 12 (Placebo 20% and 40%, respectively). Fatigue and anxiety/depression showed no significant changes. A randomised trial of 1:1 THC:CBD oil appears feasible with excellent retention and adherence, though recruitment barriers need addressing. Preliminary safety and efficacy signals warrant confirmation in larger, adequately powered trials. Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12623000345684.
What This Study Teaches Us
A 1:1 THC:CBD cannabis oil was well tolerated in 24 fibromyalgia patients over 16 weeks, with good retention and adherence. Preliminary data suggest medium to large effects on pain reduction and fibromyalgia impact scores, though fatigue and mood symptoms did not improve significantly.
Why This Matters Clinically
Fibromyalgia remains difficult to treat with conventional medications, and many patients seek cannabis alternatives. This is the first randomized controlled trial to formally test THC:CBD in this population, providing clinicians with safety and preliminary efficacy signals rather than anecdotal reports alone.
Study Snapshot
| Study Design | Double-blind, randomized, placebo-controlled pilot trial |
| Population | 24 adults with fibromyalgia (final N after randomization from 77 prescreened); demographics not specified in abstract |
| Intervention | 1:1 THC:CBD cannabis oil (10 mg/mL each), 4-week dose titration followed by 12 weeks stable dosing |
| Primary Outcome | Feasibility (recruitment, retention, adherence) and safety/tolerability |
| Key Result | 91.7% retention, ≥90% adherence, no serious adverse events; 40% of cannabis group achieved clinically meaningful fibromyalgia impact reduction (FIQR) versus 10% placebo; 70% of cannabis group reported ≥30% pain reduction versus 20-40% placebo |
Where This Paper Deserves Skepticism
This is a genuinely small pilot (N=24 total, ~12 per arm) with a 3:1 screening-to-enrollment ratio suggesting enrollment challenges and possible selection bias toward treatment-seeking patients. The 16-week duration captures only short-term tolerability; long-term safety and efficacy remain unknown. The abstract does not provide age, sex, baseline symptom severity, or dosing ranges achieved during titration, limiting generalizability assessment. No information is given about funding source or potential conflicts. Secondary efficacy outcomes in a pilot this small are preliminary signals, not confirmatory findings.
Dr. Caplan’s Take
I find this pilot encouraging because it clears the feasibility bar and shows no safety red flags in a structured trial setting. The pain and fibromyalgia impact signals are worth noting, even though the sample is small and the placebo response for pain (20-40%) reminds us that context and expectation matter significantly in fibromyalgia. I would not yet prescribe 1:1 THC:CBD as a first-line agent based on this alone, but for patients who have exhausted or poorly tolerated conventional options and express interest in cannabis, this data provides some reassurance about tolerability and a hypothesis that warrants honest discussion. A larger confirmatory trial is needed before any change in my clinical approach.
Clinical Bottom Line
This small pilot shows 1:1 THC:CBD oil is safe and well tolerated in fibromyalgia, with preliminary signals of benefit for pain and functional impact but not fatigue or mood. These findings are interesting but not sufficient to change practice, and should be interpreted as hypothesis-generating rather than confirmatory.
| |
Have thoughts on this? Share it:
